Manager TitleAgeSince
Chief Operating Officer - 13/11/2022
Director TitleAgeSince
Director/Board Member 61 15/08/2005
Chairman 67 18/09/2014
Director/Board Member 55 04/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+14.62% - - 1.28M
+0.24%-1.54%+52.85%+60.31% 53.83B
-7.17%-4.39%+42.72%+73.70% 52.1B
+0.80%-6.31%+5.62%+413.12% 23.48B
-0.09%-0.01%-16.85%-16.17% 23.13B
+4.11%+3.11%+37.43%-4.87% 19.36B
-1.14%+0.03%+31.67%-31.21% 17.56B
-5.16%-7.00%+168.44%+291.24% 15.2B
+5.57%+1.59%+35.59%+655.72% 14.83B
+0.43%-1.03%+25.75%+186.18% 14.06B
Average -0.28%-2.62%+42.58%+180.89% 25.95B
Weighted average by Cap. -1.20%-2.36%+40.86%+139.31%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
-